Veitonmäki and colleagues identified an ICAM-1 antibody (BI-505) using cellular panning of a human phage antibody library, which was tested in a phase 1 trial for myeloma therapy (47, 51). This evidence concerns the gene CACNA1A and plasma cell myeloma.